Securities Fraud Investigation Into Confluent, Inc. (CFLT) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
IF YOU ARE AN INVESTOR WHO LOST MONEY ON CONFLUENT, INC. (CFLT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 30, 2025, after market hours, Confluent released its second quarter 2025 financial results, stating that 'an AI-native customer has been making a broad-based move towards self-management of internal data platforms, reducing their Confluent Cloud usage as a result.' The Company noted that it 'continue[s] to support [the client's] data streaming needs and have now closed a Confluent Platform deal with them in Q3. This represents a significant reduction in total spending with Confluent starting in Q4 and is expected to dampen [Confluent's] Q4 cloud revenue growth rate by low single digits.'
On this news, Confluent's stock price fell $8.67, or 32.8%, to close at $17.73 per share on July 31, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Confluent should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Palantir's AIP contributed to accelerated revenue growth. Its growth has led to a pricey valuation, making its near-term direction less certain. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock has been on a tear since last year's U.S. presidential election. Since the election on Nov. 5, the stock is up by about 250%. While that is a considerable return, it is relatively modest compared to how the stock has performed over the last three years, when the market and Palantir were in the middle of a bear market. Amid the rising popularity of AI and its productivity solution, Palantir's returns since that time are nothing short of eye-popping. Palantir over the last three years If one had bought Palantir on Aug. 8, 2022, a $1,000 investment would be worth about $15,700 today. Three years ago, a dramatic pullback from the highs of the 2021 bull market left Palantir trading below $10 per share, the approximate level where it sold on its first day of trading on Sept. 30, 2020. Additionally, it got off to a slow start as it briefly fell below $6 per share in December 2022. Nonetheless, Palantir began moving higher in 2023, particularly after Open AI's release of an upgraded version of ChatGPT put the spotlight on generative AI. Palantir responded with its own generative AI solution, the artificial intelligence platform (AIP), in April 2023. Customers began reporting massive productivity gains. Over time, the stock's growth accelerated as revenue growth began to rise at a significantly faster rate. Consequently, the stock reached stratospheric highs, with a P/E ratio approaching 600. Although such earnings multiples can be common with growth stocks, its price-to-sales (P/S) ratio of 130 all but verifies that the market has priced the stock for perfection. That increases the odds of a dramatic fall at the slightest hint of bad news. However, few can deny the success of Palantir's investors over the last three years. Even if its near-term prospects are less clear, Palantir should succeed long term, since its tools have delivered massive productivity gains for its customers. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Micron Technology Inc. (NASDAQ:MU) designs, develops, manufactures, and sells memory and storage products globally. It is set to report its Q4 2025 earnings on Sept. 24. Wall Street analysts expect the company to post EPS of $2.51, up from $1.18 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $10.73 billion, up from $7.75 billion a year earlier. Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. If You Bought Micron Technology Stock 10 Years Ago The company's stock traded at approximately $18.91 per share 10 years ago. If you had invested $10,000, you could have bought roughly 529 shares. Currently, shares trade at $108.16, meaning your investment's value could have grown to $57,197 from stock price appreciation alone. However, Micron Technology also paid dividends during these 10 years. Micron Technology's dividend yield is currently 0.43%. Over the last 10 years, it has paid about $1.79 in dividends per share, which means you could have made $947 from dividends alone. Summing up $57,197 and $947, we end up with the final value of your investment, which is $58,144. This is how much you could have made if you had invested $10,000 in Micron Technology stock 10 years ago. This means a total return of 481.44%. In comparison, the S&P 500 total return for the same period is 258.20%. Trending: Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— What Could The Next 10 Years Bring? Micron Technology has a consensus rating of "Buy" and a price target of $149.07 based on the ratings of 28 analysts. The price target implies more than 37% potential upside from the current stock price. The company on June 25 announced its Q3 2025 earnings, posting revenues of $9.3 billion, beating the consensus estimate of $8.87 billion. The company reported adjusted EPS of $1.91, above the consensus of $1.60. Micron expects Q4 revenue of $10.7 billion, plus or minus $300 million, versus estimates of $9.88 billion. Adjusted EPS is expected to be $2.50, plus or minus $0.15, versus the consensus of $2.01 per out this article by Benzinga for P/E ratio insights for Micron Technology. Given the historical stock price appreciation and expected upside potential, growth-focused investors may find Micron Technology stock attractive. Furthermore, they can benefit from the company's modest dividend yield of 0.43%. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's , starting article If You Invested $10K In Micron Technology Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Why Iovance Biotherapeutics Stock Plummeted Today
Key Points Investors were hardly pleased by the company's double miss on second-quarter results. At least its revenue guidance was in line with expectations. 10 stocks we like better than Iovance Biotherapeutics › Investors are typically quite harsh on publicly traded companies that don't make their quarterly estimates, a dynamic vividly on display Friday with biotech stock Iovance Biotherapeutics (NASDAQ: IOVA). The company published its second-quarter earnings after market close the previous day, and the market reacted by trading the stock down by more than 20%. Amtagvi leads the way Iovance, a commercial-stage biotech that's focused on cell therapies for cancer treatment, reported slightly under $60 million in revenue for the period, which was nearly double the $31 million it earned in the same quarter of 2024. All of this is derived from sales of two products: Amtagvi and Proleukin. The former was by far the company's star, with over $54 million in sales. The steep increase in sales didn't filter down into a net profit, however. In fact, Iovance's GAAP (generally accepted accounting principles) net loss deepened during the quarter, coming in at almost $112 million ($0.33 per share) from the year-ago deficit of $97 million. Also, analysts were expecting Iovance to boost its top line even more. Their consensus estimate for revenue was a shade over $67 million. As for net loss, they were modeling a deficit of only $0.28 per share. In its earnings release, Iovance nevertheless sounded a bullish note about the future of its two commercialized products. It quoted CEO Frederick Vogt as saying that "Growth for Amtagvi and Proleukin will continue in the second half of 2025 as existing authorized treatment center growth continues and large community practices begin treating patients." No move on revenue guidance Investors might have liked to see that statement bolstered by a guidance raise. However, Iovance stuck to its existing forecast of $250 million to $300 million anchored, of course, by Amtagvi. The company pointed out that this is the first full year of Amtagvi sales, implying the future should be much rosier for the product. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Plummeted Today was originally published by The Motley Fool Sign in to access your portfolio
